Talecris Responds to U.S. Federal Trade Commission Filing of Complaint to Challenge Proposed CSL Transaction

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--May 28, 2009 - Talecris Biotherapeutics, Inc. yesterday was informed that the U.S. Federal Trade Commission (FTC) would file an administrative complaint challenging CSL's proposed acquisition of Talecris and a complaint in U.S. Federal District Court to enjoin the transaction.

In response, Lawrence D. Stern, Talecris' Chairman and Chief Executive Officer said, “We continue to believe that this transaction is pro-competitive for our industry and in the best interests of our patients, customers, employees, sponsors, and lenders. The combination of CSL and Talecris would materially increase IGIV capacity in the next several years.” The combination of CSL and Talecris would result in:

  • A firm with one of the broadest portfolios in the global industry with key products in each plasma therapeutic area;
  • One of the most robust and efficient plasma collection capabilities in the industry, to better assure supply of plasma for manufacturing essential therapies; and,
  • Expanded and integrated manufacturing with greater efficiency and improved ability to increase capacity, particularly with Gamunex given continued growth in the global IGIV markets.

CSL has announced that it intends to vigorously oppose the FTC's actions. Talecris will continue to support CSL in its efforts to complete the merger. Meanwhile, Talecris remains highly committed to its patient communities and delivering on its financial commitments.

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, and hemostasis. Talecris is proudly building upon a 60-year legacy of innovation and a commitment to improving the lives of people who rely on its therapeutic products. With an emphasis on scientific inquiry and technological excellence, Talecris is expanding its current portfolio of products, programs, and services through its own world-class product development organization as well as through strategic initiatives that leverage its strengths with those of its partners.

Talecris, with revenues of approximately $1.4 billion in 2008, is headquartered in biotech hub Research Triangle Park, N.C., and employs more than 4,500 talented people worldwide.

To learn more about Talecris and how our employees are making a difference in the lives of patients and the healthcare community, visit www.talecris.com.

 

 

Contact: Talecris Biotherapeutics, Inc.
Wendy Wilson, 919-316-2430
Fax: 919-316-6377
wendy.wilson@talecris.com

 

 

Posted: May 2009


View comments

Hide
(web1)